Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio

ALS Data For Verdiperstat Expected In 2022

The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.

A Businessperson Stopping Colorful Dominoes From Falling On Desk
Late-stage failures have stopped Biohaven from achieving success outside of its migraine pipeline • Source: Alamy

Biohaven Pharmaceutical Holding Company Ltd. wants to be a player in neurological and neuropsychiatric diseases, but the company has yet to report a clinical trial success outside of its CGRP inhibitor platform for the treatment of migraine. The most recent setback, disclosed on 27 September, is the failure of the myeloperoxidase (MPO) enzyme inhibitor verdiperstat in multiple system atrophy (MSA) to differentiate from placebo on the primary and secondary endpoints in a Phase III trial.

Analysts consistently viewed the setback as a minor event for Biohaven since the company’s valuation is largely based on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By 

François Roger believes fixing inefficiencies is more important than playing with pricing.

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

More from R&D

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.